COVID-19 in Parkinson's disease: Report on prevalence and outcome

Abstract

Coronavirus Disease-2019 (COVID-19) is a global pandemic with more than five million confirmed cases worldwide. COVID-19 has had a relevant impact in the field of Neurology, challenging the management of patients with chronic neurologic conditions who have, or are at risk for, the infection [[1]Papa S.M. Brundin P. C Fung V.S. Kang U.J. Burn D.J. Colosimo C. Chang H. Alcalay R.N. Trenkwalder C. MDS-scientific issues committee, impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.Mov. Disord. 2020; 35: 711‐715https://doi.org/10.1002/mds.28067Crossref PubMed Scopus (112) Google Scholar,[2]Li Y.C. Bai W.Z. Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J. Med. Virol. 2020; ([Epub ahead of print])https://doi.org/10.1002/jmv.25728Crossref Scopus (1373) Google Scholar]. Parkinson's disease (PD), affecting 1–2 per 1000 of the population at any time, and 1% of the population above 60 years, is the second most common neurodegenerative disease, with over 250,000 patients in Italy, and over 1,000,000 in USA. The potential neurotropism of COVID-19 and the finding of antibodies against coronavirus in the cerebrospinal fluid of PD patients prompted questions about the susceptibility of PD patients to COVID-19 [2Li Y.C. Bai W.Z. Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J. Med. Virol. 2020; ([Epub ahead of print])https://doi.org/10.1002/jmv.25728Crossref Scopus (1373) Google Scholar, 3Antonini A A. Leta V. Teo J. Chaudhuri K.R. Outcome of Parkinson's disease patients affected by COVID-19.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28104Crossref Scopus (148) Google Scholar, 4Cilia R. Bonvegna S. Straccia G. Andreasi Nico G. Elia A.E. Romito L.M. Devigili G. Cereda E. Eleopra R. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28170Crossref Scopus (110) Google Scholar, 5Fasano A. Cereda E. Barichella M. Cassani E. Ferri V. L Zecchinelli A. Pezzoli G. COVID-19 in Parkinson's disease patients living in Lombardy, Italy.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28176Crossref Scopus (103) Google Scholar, 6Hainque E. Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection.Park. Relat. Disord. 2020; (30117-6): S1353-S8020https://doi.org/10.1016/j.parkreldis.2020.05.008Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar]. To date, only two case series for a total of 12 PD patients and one community-based study were published about PD and COVID-19 [[3]Antonini A A. Leta V. Teo J. Chaudhuri K.R. Outcome of Parkinson's disease patients affected by COVID-19.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28104Crossref Scopus (148) Google Scholar,[4]Cilia R. Bonvegna S. Straccia G. Andreasi Nico G. Elia A.E. Romito L.M. Devigili G. Cereda E. Eleopra R. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28170Crossref Scopus (110) Google Scholar,[6]Hainque E. Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection.Park. Relat. Disord. 2020; (30117-6): S1353-S8020https://doi.org/10.1016/j.parkreldis.2020.05.008Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar], suggesting worsening of motor and non-motor symptoms and an association between higher mortality rates (40%) and older age and longer PD duration [[3]Antonini A A. Leta V. Teo J. Chaudhuri K.R. Outcome of Parkinson's disease patients affected by COVID-19.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28104Crossref Scopus (148) Google Scholar,[4]Cilia R. Bonvegna S. Straccia G. Andreasi Nico G. Elia A.E. Romito L.M. Devigili G. Cereda E. Eleopra R. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28170Crossref Scopus (110) Google Scholar]. Also, a recent large case-control study performed on a single-center in Lombardy, Italy, reported an interview to non-advanced PD patients [[5]Fasano A. Cereda E. Barichella M. Cassani E. Ferri V. L Zecchinelli A. Pezzoli G. COVID-19 in Parkinson's disease patients living in Lombardy, Italy.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28176Crossref Scopus (103) Google Scholar]. The authors found a similar rate of infection in PD patients and controls and suggest that COVID-19 risk and mortality did not differ from the general population. However, the prevalence of PD patients affected by COVID-19 is still unknown [[1]Papa S.M. Brundin P. C Fung V.S. Kang U.J. Burn D.J. Colosimo C. Chang H. Alcalay R.N. Trenkwalder C. MDS-scientific issues committee, impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.Mov. Disord. 2020; 35: 711‐715https://doi.org/10.1002/mds.28067Crossref PubMed Scopus (112) Google Scholar]. Here, we aimed to estimate the prevalence of COVID-19 in a large population of PD patients and compare the infection rate with the general population of the same region. To this end, we interviewed a large cohort of PD patients living in Piedmont, a northern Italian region presenting the second-highest number of COVID-19 cases in Italy after Lombardy, and having a population of 4,356,406, with an estimated number of PD patients of about 13,000–15,000. The regional section of the Italian Association of Parkinsonian patients reached out by phone and interviewed 1,407 PD patients (or their caregivers) on 4–6 May 2020, asking for a laboratory-confirmed diagnosis of COVID-19. This screening interview was conducted spontaneously by the Association, which involved all members reachable by phone, in the absence of any selection criterion. Aggregated data provided by the association about members were: 62% males, 47% of patients with an age >75 years, disease duration ranging from 1 to >25 years, 1% in nursing home. This information makes of the interviewees a heterogeneous cohort of PD patients living in Piedmont, and we do not see potentially relevant selection bias in terms of sex, age, income, disease duration, or disease stage since the association includes all PD patients and their families on a volunteer basis and without limitations related to demographic or clinical features. In cases of confirmed positivity to COVID-19, the Association asked for the possibility of data collection for research purposes, and information on PD, therapy, comorbidities, and outcome was retrieved by an experienced neurologist (C.A.A.) by a semi-structured phone interview. The Local Ethical Committee approved the study, and all participants interviewed for research purposes provided a documented and witnessed verbal informed consent, obtained after a structured and detailed explanation of objectives and use of data, according to the guidelines of the Declaration of Helsinki. Eight PD patients, meaning 0.57% of interviewed, were found to be positive to COVID-19. The number of positive cases in Piedmont at the date of May 4, 2020 was 27,622, with a prevalence of 0.63%. 75% of PD patients (n = 6/8) died because of COVID-19, while the mortality rate in the general population of Piedmont was 11.53% (n = 3186/27,622). Demographic and clinical data of infected PD patients are reported in Table 1. PD symptoms worsened in all patients, early before or early after the onset of infection signs, which consisted in fever (100% of patients), weakness (43%), muscle pain (29%), dyspnea (29%), and cough (14%). Interestingly, one patient developed disabling dyskinesia as the presenting symptom of the infection. All patients were hospitalized, and three were already institutionalized at the moment of infection. All were treated with levodopa, alone or in combination with dopamine agonists. One patient was treated with levodopa/carbidopa intestinal gel infusion plus entacapone. PD therapy was modified in two cases: in one case, the dosage of levodopa was increased, while in the other dopaminergic therapy was stopped as the patient's conditions worsened.Table 1Demographic and clinical information of parkinsonian patients with COVID-19.PatientSexAgePD durationComorbiditiesPD TherapyInstitutionalizationCOVID-19 symptomsWorsening of PDChange of PD therapyOutcome1F645HypertensionLevodopa/carbidopa,PramipexoleNoFever, Asthenia, Muscle painNoNoRecovery2M7720Lung neoplasm (steady - in follow-up)Levodopa/carbidopaYesFever, Asthenia,Cough,DyspneaYes: dysphagia and inability to standYes: stopped after infection worseningDeath3F743DepressionLevodopa/benserazide,PramipexoleNoFever, Asthenia, Muscle painYes: worsening of rigidity and bradykinesiaNoDeath4M6321Diabetes in diet therapyMelevodopa/carbidopaYesFever,DyspneaNot assessable: patients already bedridden and fed with PEGNoDeath5F8116Hypertension, hyperhomocysteinemiaLevodopa/carbidopa gel intestinal infusion, EntacaponeNoFever,DyspneaYes: onset of disabling dyskinesiaNoDeath6M7915NALevodopa/carbidopaNANANANADeath7*M805Hypertension, atrial fibrillation, benign prostatic hyperplasiaLevodopa/carbidopaYesFever, coughYes: in particular worsening of dysphagiaYes: increase in levodopa doseRecovery8MNANANANANANANANADeathPEG: percutaneous endoscopic gastrostomy.NA: information not available.*The patient reported some atypical parkinsonian symptoms/signs.Caregivers of patients #6 and #8 did not accept to disclose further information, except those reported in the Table. Open table in a new tab PEG: percutaneous endoscopic gastrostomy. NA: information not available. *The patient reported some atypical parkinsonian symptoms/signs. Caregivers of patients #6 and #8 did not accept to disclose further information, except those reported in the Table. To our knowledge, this is the first report of the prevalence of confirmed COVID-19 cases in a large cohort of PD patients living in a specific geographic area. Notably, the prevalence was equivalent to that of the general population. Whether a similar prevalence is related to the same predisposition for COVID-19 infection or to a higher level of attention and self-isolation in PD patients (as an at-risk population) cannot be elucidated by our data. However, differently from a previous similar study, we found a high rate of mortality among PD patients [[5]Fasano A. Cereda E. Barichella M. Cassani E. Ferri V. L Zecchinelli A. Pezzoli G. COVID-19 in Parkinson's disease patients living in Lombardy, Italy.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28176Crossref Scopus (103) Google Scholar]. This discrepancy might be due to the fact that the study of Lombardy patients did not consider advanced PD patients and those living in nursing homes or other long-term care facilities. On the other hand, another study considering the outcome of PD patients affected by COVID-19 found a ‘substantially high mortality rate (40%)’, suggesting that older age and longer disease duration might be predictors of worse outcomes [[3]Antonini A A. Leta V. Teo J. Chaudhuri K.R. Outcome of Parkinson's disease patients affected by COVID-19.Mov. Disord. 2020; ([Epub ahead of print])https://doi.org/10.1002/mds.28104Crossref Scopus (148) Google Scholar]. Limitations intrinsic to this kind of study notwithstanding, our data might cautiously suggest that PD patients should not be necessarily considered at higher risk for developing COVID-19, but might be at higher risk for a worse outcome, especially if they have a long PD duration. Further studies on larger cohorts of PD patients affected by COVID-19 are needed to confirm this finding.